Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 70518-4154

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 70518-4154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is information about Venlafaxine, an extended-release medication in the dose of 150 mg. The medication comes in a capsule form with a quantity of 30 capsules. The manufacturer is Epic Pharma, LLC, located in Laurelton, NY. The directions for use are mentioned to refer to the package insert. It should be stored at temperatures between 20-25°C (58-77°F) with excursions permitted to 15.30°C (59-86°F). The medication should be kept out of the reach of children. Additionally, it was repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Image-01 (Image 01)

FDA Label Image

Image-02 (Image 02)

This text includes information related to special healthcare considerations for hepatic and renal impairment, as well as specific considerations for aging populations, gender differences, and genetic variability affecting drug metabolism. The document also mentions variations in analyte levels and fold change data, indicating potential impacts on pharmacokinetics. These details can be valuable in understanding drug effects and dosing adjustments in various patient populations.*

FDA Label Image

Image-03 (Image 03)

This is a list of drug-drug interactions showing the fold change and 90% confidence interval for various drug analytes when interacting with venlafaxine and other medications such as ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium. The text also includes information on interactions based on different CYP2D6 phenotypes. The data seems to compare the maximum concentration (Cmax) and area under the curve (AUC) for these drug combinations. This information can be useful in understanding how these medications may influence each other's pharmacokinetics.*

FDA Label Image

Image-04 (Image 04)

This appears to be a list of interacting drugs, analytes, and active moieties along with fold change and 90% confidence intervals. The drugs include Ethanor, Diazepam, Alprazolam, Indinavic, Metoprolol, Risperidone, Imipramine, Haloperidol, Caffeine, Tolbutamide, and Lithium. The text mentions various derivatives and metabolites of these drugs as well. Additionally, it outlines the fold change relative to a reference value for each drug.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.